In this study, we sought to address this knowledge gap by investigating the prevalence of IFN-α2 and/or IFN-ω neutralizing antibodies and their correlation with clinical outcomes in Chinese COVID-19 patients during an outbreak of the SARS-CoV-2 Omicron variant in a multicenter cohort in Shanghai, China. This evidence concerns the gene IFNA2 and COVID-19.